<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Healthcare</title>
	<atom:link href="http://www.stockbloghub.com/category/healthcare/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(QGEN) Qiagen Beats Earnings Forecasts &#8211; Reiterates Outllook</title>
		<link>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817</link>
		<comments>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817#comments</comments>
		<pubDate>Mon, 30 Apr 2012 18:00:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99817</guid>
		<description><![CDATA[Qiagen’s (QGEN) first quarter 2012 earnings of 12 cents per share remained flat on a year-over-year basis. However, adjusting for certain one-time items, EPS came in at 23 cents in the first quarter, beating the Zacks Consensus Estimate of 19 cents as well as the year-ago quarter earnings by a couple of cents. The improvement in the bottom line was driven by double–digit sales growth and efficient cost management. In the fourth quarter, all the operational regions of the company delivered double-digit growth at CER. Region wise, Americas (47% of revenues) witnessed a 15% increase in sales at CER, driven by strong contributions from the US, Brazil and Canada. However, revenues from Europe- Middle East-Africa (34% of sales) and Asia-Pacific /Japan (18% of sales) increased 12% and 18% at CER, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALGN) Align Technology Posts Solid First Quarter Earnings</title>
		<link>http://www.stockbloghub.com/2012/04/28/algn-align-technology-posts-solid-first-quarter-earnings/99568</link>
		<comments>http://www.stockbloghub.com/2012/04/28/algn-align-technology-posts-solid-first-quarter-earnings/99568#comments</comments>
		<pubDate>Sat, 28 Apr 2012 20:05:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[ALGN]]></category>
		<category><![CDATA[Align Technology Inc]]></category>
		<category><![CDATA[American Strategic Income Portfolio Inc]]></category>
		<category><![CDATA[ASP]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99568</guid>
		<description><![CDATA[Align Technology (ALGN) reported first quarter 2012 EPS of 26 cents, which was 30% higher than the year-ago level. Adjusting for certain one-time items, the adjusted EPS came in at 27 cents, beating the Zacks Consensus Estimate of 22 cents as well as the year-ago quarter adjusted EPS of 21 cents. The adjusted EPS also surpassed the company’s guidance range of 19?21 cents. Total revenue increased 28.7% year over year to $135.1 million in the quarter, exceeding the Zacks Consensus Estimate of $129 million and the company’s guidance of $125.4?$127.9 million. Total Invisalign clear aligner revenue came in at $123.3 million, up 17.6% year over year, driven by case shipments of 85.3 thousand (up 19.5%) during the quarter. Scanner and CAD/CAM services revenues were $11.8 million in the reported quarter, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/28/algn-align-technology-posts-solid-first-quarter-earnings/99568/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HUM) Attention Shifts to Jobs &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2012/04/28/hum-attention-shifts-to-jobs-earnings-preview/99859</link>
		<comments>http://www.stockbloghub.com/2012/04/28/hum-attention-shifts-to-jobs-earnings-preview/99859#comments</comments>
		<pubDate>Sat, 28 Apr 2012 20:04:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADM]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[AIG]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[AM]]></category>
		<category><![CDATA[American Greetings Corporation]]></category>
		<category><![CDATA[American International Group Inc]]></category>
		<category><![CDATA[Archer-Daniels-Midland Company]]></category>
		<category><![CDATA[Automatic Data Processing Inc]]></category>
		<category><![CDATA[Avon Products Inc.]]></category>
		<category><![CDATA[AVP]]></category>
		<category><![CDATA[Cablevision Systems Corporation]]></category>
		<category><![CDATA[CBS]]></category>
		<category><![CDATA[CBS Corporation]]></category>
		<category><![CDATA[CMCSA]]></category>
		<category><![CDATA[Comcast Corporation]]></category>
		<category><![CDATA[CVC]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[EL]]></category>
		<category><![CDATA[Estee Lauder Companies Inc.]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[KFT]]></category>
		<category><![CDATA[Kraft Foods Inc.]]></category>
		<category><![CDATA[L]]></category>
		<category><![CDATA[Loews Corporation]]></category>
		<category><![CDATA[MA]]></category>
		<category><![CDATA[Mastercard Incorporated]]></category>
		<category><![CDATA[Nyse Euronext Inc]]></category>
		<category><![CDATA[NYX]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[Time Warner Inc.]]></category>
		<category><![CDATA[TWX]]></category>
		<category><![CDATA[V]]></category>
		<category><![CDATA[VIAB]]></category>
		<category><![CDATA[Viacom]]></category>
		<category><![CDATA[Visa Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99859</guid>
		<description><![CDATA[Earnings Preview – Week of April 30th The focus this week will be on the labor market, with the April non-farm payroll report coming out on Friday. Many will be hoping that this report will provide confirmation that last month’s disappointment was just a one-off event and the positive trend line of the preceding months is still in place. Jobs aside, we are still in the midst of the first quarter 2012 reporting season, though we have crossed the mid-point of the cycle with about 60% of the results already in. With another 124 S&#38;P 500 companies reporting results in the coming week, we will have results from roughly 84% of the companies by the end of this week. The first quarter earnings season has turned out to be much ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/28/hum-attention-shifts-to-jobs-earnings-preview/99859/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) St. Jude Medical Build on Alliance with Abbott Laboratories</title>
		<link>http://www.stockbloghub.com/2012/04/28/stj-st-jude-medical-build-on-alliance-with-abbott-laboratories/99648</link>
		<comments>http://www.stockbloghub.com/2012/04/28/stj-st-jude-medical-build-on-alliance-with-abbott-laboratories/99648#comments</comments>
		<pubDate>Sat, 28 Apr 2012 20:03:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[FFR]]></category>
		<category><![CDATA[First Trust FTSE EPRA-NAREIT Glb Real Es]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99648</guid>
		<description><![CDATA[St. Jude Medical Inc. (STJ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories (ABT) by revealing the long-term Choice Alliance joint venture. This initiative provides St. Jude Medical the opportunity to incorporate Abbott&#8217;s drug-eluting stents with its cardiovascular, cardiac rhythm management and electrophysiology offerings. Both companies have agreed to endorse each other’s products to their respective customers. Further, Abbott has received the rights to promote St. Jude’s RadiAnalyze Xpress Measurement System and the ILUMIEN PCI Optimization System. This alliance is expected to benefit patient outcomes, as doctors will be able to combine Abbott’s XIENCE family of stents with St. Jude’s optical coherence tomography (OCT) and fractional flow reserve (FFR) know-how to widen the scope of clinical treatments. Abbott Laboratories is a global manufacturer of a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/28/stj-st-jude-medical-build-on-alliance-with-abbott-laboratories/99648/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Intuitive Surgical Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/04/26/isrg-intuitive-surgical-incorporated-bull-of-the-day-2/99638</link>
		<comments>http://www.stockbloghub.com/2012/04/26/isrg-intuitive-surgical-incorporated-bull-of-the-day-2/99638#comments</comments>
		<pubDate>Thu, 26 Apr 2012 18:09:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99638</guid>
		<description><![CDATA[We upgrade our rating for Intuitive Surgical, Inc. (ISRG) to Outperform. First quarter earnings per share of $3.50 beat the Zacks Consensus Estimate. Gynecology and prostatectomy procedures did well in 2011, as did certain emerging procedures. Recurring revenue continues to grow as a proportion of sales. In the interim, the installed base of Intuitive is expanding as more hospitals feel compelled to upgrade their technology. Overall, a proper valuation is appropriate given positive factors such as Intuitive&#8217;s leading position in robotic surgery, a growing list of emerging procedures, barriers to entry, sizeable cash balance and no debt. We like the company&#8217;s da Vinci system, particularly its unique status as an enabler of robotic, minimally invasive surgery. Our target price of $701 is based on a P/E of 48.2x our fiscal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/26/isrg-intuitive-surgical-incorporated-bull-of-the-day-2/99638/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(UNH) UnitedHealth Group &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/04/26/unh-unitedhealth-group-bull-of-the-day-4/99626</link>
		<comments>http://www.stockbloghub.com/2012/04/26/unh-unitedhealth-group-bull-of-the-day-4/99626#comments</comments>
		<pubDate>Thu, 26 Apr 2012 18:08:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99626</guid>
		<description><![CDATA[UnitedHealth Group&#8217;s (UNH) first quarter earnings came in significantly ahead of the Zacks Consensus Estimates on the back of strong revenue growth at UnitedHealthcare as well as Optum businesses and strong enrollment growth. We are bullish about the company&#8217;s long-term growth prospects. UnitedHealth has strengthened its key capabilities to respond to the emerging growth opportunities. These initiatives have been taken to expand its Medicaid and Medicare business, growing the health service business and expanding international operations. Though certain headwinds remain, we believe the company will beat the odds given its diversified business model with leading market share positions in the Commercial, Medicare, and Medicaid markets. Our six-month target price of $70.00 equates to about 14.1x our earnings estimate for 2012. We view the $0.65 per common share annual dividend as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/26/unh-unitedhealth-group-bull-of-the-day-4/99626/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(IART) Integra LifeScience Holdings Corporation Earns FDA Nod for Spine Device</title>
		<link>http://www.stockbloghub.com/2012/04/23/iart-integra-lifescience-holdings-corporation-earns-fda-nod-for-spine-device/99408</link>
		<comments>http://www.stockbloghub.com/2012/04/23/iart-integra-lifescience-holdings-corporation-earns-fda-nod-for-spine-device/99408#comments</comments>
		<pubDate>Mon, 23 Apr 2012 15:31:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[IART]]></category>
		<category><![CDATA[Integra LifeSciences Holdings Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99408</guid>
		<description><![CDATA[Global provider of surgical implants and medical instruments, Integra LifeScience Holdings Corporation (IART) recently received the 510(k) clearance from the US Food and Drug Administration (FDA) for its path-breaking Integra Vu aPOD Prime Inter-vertebral Body Fusion Device (IBD), a zero profile IBD designed for anterior lumbar fusion (ALIF) procedures. The company also showcased the product at the annual meeting of the American Association of Neurological Surgeons held between April 14 &#8211; 18, 2012 in Florida. IBDs are small, hollow spinal implants that provide stability for spinal fusion after the surgical removal of a diseased lumbar disc. To restore the physiological disc height and allow fusion between vertebral bodies, these particles are inserted into the inter-vertebral space. While conventionally surgeons need supplemental fixation to hold the IBD in place, this new ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/23/iart-integra-lifescience-holdings-corporation-earns-fda-nod-for-spine-device/99408/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) St. Jude Beats The Street &#8211; Raises Guidance</title>
		<link>http://www.stockbloghub.com/2012/04/20/stj-st-jude-beats-the-street-raises-guidance/98962</link>
		<comments>http://www.stockbloghub.com/2012/04/20/stj-st-jude-beats-the-street-raises-guidance/98962#comments</comments>
		<pubDate>Fri, 20 Apr 2012 17:26:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Salesforce.com]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=98962</guid>
		<description><![CDATA[St. Jude Medical, Inc. (STJ), a large-cap medical devices and technology development company, reported first quarter fiscal 2012 adjusted earnings of 86 cents beating the Zacks Consensus Estimate of 83 cents per share and surpassing the year-ago earnings of 80 cents per share. Adjusted earnings exclude extraordinary and one-time charges such as restructuring expenses to modernize manufacturing in the Cardiac Rhythm Management (CRM) segment. In the reported quarter, profit dropped 9% to $212 million (or 67 cents a share). Revenues St. Jude reported net revenues of $1,395 million, up 1% year over year, beating the Zacks Consensus Estimate of $1,383 million. Net sales rose 2% on constant currency basis. Healthy growth across the company’s smaller Atrial Fibrillation (AF) and Neuromodulation segments were largely offset by the decline in the core ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/20/stj-st-jude-beats-the-street-raises-guidance/98962/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(UNH) Health Insurance Stock Outlook &#8211; April 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/04/20/unh-health-insurance-stock-outlook-april-2012-industry-outlook/99299</link>
		<comments>http://www.stockbloghub.com/2012/04/20/unh-health-insurance-stock-outlook-april-2012-industry-outlook/99299#comments</comments>
		<pubDate>Fri, 20 Apr 2012 17:15:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AET]]></category>
		<category><![CDATA[Aetna Inc.]]></category>
		<category><![CDATA[AGP]]></category>
		<category><![CDATA[AMERIGROUP Corporation]]></category>
		<category><![CDATA[Centene Corporation]]></category>
		<category><![CDATA[CI]]></category>
		<category><![CDATA[CIGNA Corporation]]></category>
		<category><![CDATA[CNC]]></category>
		<category><![CDATA[Coventry Health Care Inc.]]></category>
		<category><![CDATA[CVH]]></category>
		<category><![CDATA[Gartner Inc.]]></category>
		<category><![CDATA[Genworth Financial Inc.]]></category>
		<category><![CDATA[GNW]]></category>
		<category><![CDATA[Health Net Inc.]]></category>
		<category><![CDATA[HIT]]></category>
		<category><![CDATA[Hitachi Limited]]></category>
		<category><![CDATA[HNT]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[IT]]></category>
		<category><![CDATA[MA]]></category>
		<category><![CDATA[Mastercard Incorporated]]></category>
		<category><![CDATA[Miller Industries Inc]]></category>
		<category><![CDATA[MLR]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[WellPoint Inc.]]></category>
		<category><![CDATA[WLP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99299</guid>
		<description><![CDATA[Though the U.S. Health insurance industry continues to be relatively immune to economic difficulties, it has been still grappling with fundamental changes and consequent growth pangs. The industry has been facing its share of problems related to a sluggish economic recovery, uncertainty surrounding the health care reform law and increased regulatory control. Despite the odds, the industry remains profitable, with the top six players &#8212; UnitedHealth Group Inc. (UNH), CIGNA Corp. (CI), WellPoint Inc. (WLP), Aetna Inc. (AET), Humana Inc. (HUM), Coventry Health Care Inc. (CVH) &#8212; reporting year-over-year earnings growth in FY11. About the Industry The U.S. Health and Medical Insurance industry is an integral part of the U.S. economy. According to the Centers for Medicare and Medicaid Services, U.S. health expenditures account for about 18% of the country’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/20/unh-health-insurance-stock-outlook-april-2012-industry-outlook/99299/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) US Court Rejects AstraZeneca&#8217;s Case</title>
		<link>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196</link>
		<comments>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196#comments</comments>
		<pubDate>Thu, 19 Apr 2012 20:24:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97196</guid>
		<description><![CDATA[Recently, AstraZeneca (AZN) announced that US District Court for the District of Columbia has dismissed the lawsuit filed by the company against the US Food and Drug Administration (FDA). AstraZeneca had taken legal action against the FDA, challenging the agency’s decision to reject AstraZeneca’s Citizen Petitions. The Citizen Petitions were filed by the company for Seroquel (quetiapine fumarate) and Seroquel XR. The Citizen Petitions were filed to bar the FDA from approving any generic versions of the drug that do not include warnings related to hyperglycemia and suicidality in its label. With this move, AstraZeneca was looking to delay the launch of generic versions of Seroquel considering the company has marketing exclusivity for the data associated with the hyperglycemia warning till December 2, 2012. Meanwhile, the UK High Court has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALXN) Alexion Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/04/19/alxn-alexion-pharmaceuticals-bull-of-the-day-2/99142</link>
		<comments>http://www.stockbloghub.com/2012/04/19/alxn-alexion-pharmaceuticals-bull-of-the-day-2/99142#comments</comments>
		<pubDate>Thu, 19 Apr 2012 18:28:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99142</guid>
		<description><![CDATA[We are upgrading Alexion Pharmaceuticals (ALXN) to Outperform from Neutral on valuation grounds; we believe that there is significant upside scope from current levels. Alexion performed very well in the final quarter of 2011, beating the Zacks Consensus Estimate by $0.07 thanks to strong Soliris sales. We are also impressed by the label expansion of Soliris in the US and EU for the aHUS indication, which has boosted the sales potential of the drug. We expect Soliris to continue performing well in 2012. Consequently, we have increased our revenue estimate for 2012 and expect Soliris sales to exceed $1 billion in 2012. Management, too, gave a bright outlook for 2012. Our long-term recommendation is in line with the Zacks #1 Rank (Strong Buy rating) carried by the stock in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/19/alxn-alexion-pharmaceuticals-bull-of-the-day-2/99142/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Active on the Generics Front</title>
		<link>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937</link>
		<comments>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937#comments</comments>
		<pubDate>Mon, 09 Apr 2012 18:03:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97937</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic products are Teva’s generic versions of Sanofi’s (SNY) high blood pressure drugs, Avapro and Avalide, AstraZeneca’s (AZN) schizophrenia treatment, Seroquel, and Forest Laboratories’ (FRX) Lexapro. While Teva will enjoy a 180-day period of marketing exclusivity where the generic launches of Avapro, Avalide and Lexapro are concerned, we note that other generic players like Dr. Reddy’s Laboratories (RDY) and Mylan (MYL) have also launched their generic versions of Seroquel. As per IMS data, annual US sales of Avapro, Avalide, Seroquel, and Lexapro were $464 million, $124 million, $4.6 billion and $2.9 billion, respectively. Teva also launched its authorized generic of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Healthcare Reform: Bad News for Big Pharma?</title>
		<link>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425</link>
		<comments>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:56:03 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97425</guid>
		<description><![CDATA[Healthcare reform could be a minefield for Big Pharma in the long run. The Patient Protection and Affordable Care Act – less fondly known as “Obamacare” – was the big story to close out the month of March, as the Supreme Court officially took the case. In an effort to figure out which way the vote was going to swing, the media analyzed every word, pause and twitch the justices made. Though all of that heavy-duty analysis doesn’t actually prove anything; while the Court has likely already decided the healthcare mandate’s fate one way or the other, “We the People” probably won’t find out until June. Considering the political left’s repeated complaints about Solicitor General Donald Verrilli Jr. and Deputy Attorney General Edwin S. Kneedler’s admittedly painful performance in explaining ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Inks Deal with Cephalon</title>
		<link>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439</link>
		<comments>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:53:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97439</guid>
		<description><![CDATA[The recent agreement with Cephalon is another attempt by Myriad Genetics (MYGN) to establish itself as a strong player in the companion diagnostic market. Cephalon is a subsidiary of Teva Pharmaceuticals (TEVA).  Under the agreement, Myriad will conduct BRCA1 and BRCA2 mutation testing on patients with Bracanalysis before being enrolled in a phase I/II clinical study. Over the recent past, the company has entered into similar agreements with players such as Abbott (ABT), Astra Zeneca (AZN) and BioMarin Pharmaceuticals (BMRN) to provide companion diagnostic tests for clinical trial enrollment. Bracanalysis is Myriad’s flagship product, which analyzes the BRCA1 and BRCA2 genes to assess a woman&#8217;s risk for hereditary breast and ovarian cancer. Moreover, the acquisition of RBM (Rules-Based Medicine), made in 2011 would better place Myriad in this arena on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Analyst Still Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209</link>
		<comments>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209#comments</comments>
		<pubDate>Mon, 02 Apr 2012 17:37:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97209</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $8.25. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta in March 2011 for treating patients suffering from systemic lupus erythematosus (SLE) was a huge positive for Human Genome. The subsequent launch of the drug in Canada and several European nations, including Germany, Spain, Austria, Denmark, Finland, Hungary, Norway and Sweden is also encouraging. Benlysta, which has blockbuster potential, has been co-developed with GlaxoSmithKline (GSK). Benlysta is the first new lupus drug to be cleared in more than 50 years. Sales of the drug are growing, albeit slowly. Net sales of Benlysta improved 36.7% sequentially to $25.7 million in the final quarter of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories and Janssen Pharmaceutica Sue Generic Players</title>
		<link>http://www.stockbloghub.com/2012/03/19/frx-forest-laboratories-and-janssen-pharmaceutica-sue-generic-players/95647</link>
		<comments>http://www.stockbloghub.com/2012/03/19/frx-forest-laboratories-and-janssen-pharmaceutica-sue-generic-players/95647#comments</comments>
		<pubDate>Tue, 20 Mar 2012 02:16:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=95647</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and Janssen Pharmaceutica NV, a Johnson &#38; Johnson (JNJ) company, recently filed a joint lawsuit against several generic companies that are looking to launch their generic versions of Bystolic (nebivolol). The patent infringement lawsuit has been filed in the US District Court for the District of Delaware for infringement of US Patent No. 6,545,040. The lawsuit has been filed against companies like Amerigen Pharmaceuticals, Inc., Glenmark Generics, Inc., Hetero USA Inc., Torrent Pharmaceuticals Ltd., Watson Laboratories, Inc. (WPI). Another patent infringement lawsuit has been filed by Forest Labs and Janssen in the US District Court for the Northern District of Illinois against Alkem Laboratories Limited and Indchemie Health Specialties Pvt. Ltd. This lawsuit is also related to the infringement of the ‘040 patent. With the lawsuits ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/19/frx-forest-laboratories-and-janssen-pharmaceutica-sue-generic-players/95647/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) MedTech Industry Stock Outlook &#8211; March 2012 &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611</link>
		<comments>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611#comments</comments>
		<pubDate>Tue, 20 Mar 2012 02:13:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94611</guid>
		<description><![CDATA[Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure volume pressures. The difficult macroeconomic backdrop, pricing headwinds, austerity measures, reimbursement pressure, a still unstable job market and the impact of health care reform continue to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. With fewer patients going under the knife accompanied by concerns of overuse of devices, companies in the cardiovascular and orthopedic domain continue to grapple with tepid utilization. After having a buoyant first half, the MedTech sector went through a rough patch in the back half of 2011 given the weakened sector fundamentals, sluggish key end-markets ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) MedTech Industry Stock Outlook &#8211; March 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609</link>
		<comments>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609#comments</comments>
		<pubDate>Thu, 08 Mar 2012 19:28:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94609</guid>
		<description><![CDATA[Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure volume pressures. The difficult macroeconomic backdrop, pricing headwinds, austerity measures, reimbursement pressure, a still unstable job market and the impact of health care reform continue to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. With fewer patients going under the knife accompanied by concerns of overuse of devices, companies in the cardiovascular and orthopedic domain continue to grapple with tepid utilization. After having a buoyant first half, the MedTech sector went through a rough patch in the back half of 2011 given the weakened sector fundamentals, sluggish key end-markets ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Risk-Reward Balanced at Alkermes</title>
		<link>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426</link>
		<comments>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426#comments</comments>
		<pubDate>Wed, 07 Mar 2012 17:19:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94426</guid>
		<description><![CDATA[We are maintaining a Neutral rating on Alkermes (ALKS) with a target price of $18.00. Last month, Alkermes released its third quarter fiscal 2012 (ended December 31, 2011) financial results.  This was the first full quarter for Alkermes plc, formed in September 2011, following the merger of Waltham, Massachusetts based Alkermes, Inc. and Elan Drug Technologies (EDT), the drug delivery unit of  Elan Corporation (ELN). The merger has expanded the portfolio significantly resulting in a 185.7% increase in revenues during the quarter. The expanded portfolio caused management to increase the 2012 revenue projection. Revenues are projected in the range of $370-$400 million, up from the previous guidance of $350-$380 million. Given the expanded product portfolio, we expect the company to achieve/beat the increased guidance. Consequently, the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Earns Positive News on Pipeline</title>
		<link>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441</link>
		<comments>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441#comments</comments>
		<pubDate>Tue, 06 Mar 2012 21:31:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94441</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) recently reported back-to-back positive news on the pipeline front. The company and partner Gedeon Richter Plc. announced that their late-stage anti-psychotic candidate, cariprazine, met its primary endpoint in two phase III studies. The studies were conducted to evaluate cariprazine for the treatment of acute exacerbation of schizophrenia. Results showed that patients in the cariprazine arm achieved a significant improvement in symptom compared to patients in the placebo arm. Statistically significant separation from placebo was observed in all doses from week 2 and at each subsequent time point. Forest Labs and Gedeon said that the higher dose showed separation as early as week 1 of treatment.  The results were similar to data presented earlier from a phase IIb fixed-dose placebo-controlled study. Cariprazine is one of the candidates ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon&#8217;s Provenge Showing Bleak Outlook</title>
		<link>http://www.stockbloghub.com/2012/03/05/dndn-dendreons-provenge-showing-bleak-outlook/93847</link>
		<comments>http://www.stockbloghub.com/2012/03/05/dndn-dendreons-provenge-showing-bleak-outlook/93847#comments</comments>
		<pubDate>Mon, 05 Mar 2012 15:19:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=93847</guid>
		<description><![CDATA[Dendreon Corporation (DNDN) reported fourth-quarter 2011 earnings (including stock-based compensation expense but excluding other special items) of 37 cents per share, in contrast to the Zacks Consensus Estimate loss of 31 cents and year-ago loss of 60 cents per share. Full-year loss of $1.68 per share (excluding special items but including stock-based compensation expense) were narrower than the Zacks Consensus Estimate of a loss of $2.83 and the year-ago loss of $3.07 per share. Total revenue in the reported quarter climbed to $202.1 million from $25.0 million in the comparable quarter of 2010. We note, however, that revenue in the reported quarter included one time royalty revenue of $125 million related to sale of its royalty interest in Merck, Inc.’s (MRK) hepatitis C product Victrelis. Excluding this one-time revenue, Dendreon ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/05/dndn-dendreons-provenge-showing-bleak-outlook/93847/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Analyst Maintains Neutral Share rating</title>
		<link>http://www.stockbloghub.com/2012/02/24/prgo-perrigo-analyst-maintains-neutral-share-rating/92526</link>
		<comments>http://www.stockbloghub.com/2012/02/24/prgo-perrigo-analyst-maintains-neutral-share-rating/92526#comments</comments>
		<pubDate>Fri, 24 Feb 2012 18:21:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=92526</guid>
		<description><![CDATA[We have maintained our Neutral rating on Perrigo Company (PRGO) with a target price of $100.00 following appraisal of second quarter of fiscal 2012 results. Perrigo reported second quarter EPS of $1.20, beating the Zacks Consensus Estimate of $1.16 and the year-earlier earnings of $1.05 per share. A robust top-line performance boosted earnings in the quarter. Strong performance by Rx Pharmaceuticals and new products led to the sales growth. Perrigo is a dominant player in the store brand over the counter (OTC) drug market. We believe that Perrigo’s strong position in the brand OTC pharmaceutical market and growing generics and API businesses will help it deliver solid top- and bottom-line growth in the coming years. In the OTC pharmaceutical market, products are sold due to changes in product status from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/24/prgo-perrigo-analyst-maintains-neutral-share-rating/92526/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GB) Greatbatch Buying NeuroNexus</title>
		<link>http://www.stockbloghub.com/2012/02/23/gb-greatbatch-buying-neuronexus/92142</link>
		<comments>http://www.stockbloghub.com/2012/02/23/gb-greatbatch-buying-neuronexus/92142#comments</comments>
		<pubDate>Thu, 23 Feb 2012 19:36:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[GB]]></category>
		<category><![CDATA[Greatbatch Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=92142</guid>
		<description><![CDATA[Medical technology company Greatbatch (GB) is acquiring Michigan-based implantable medical device design firm NeuroNexus Technologies for roughly $12 million. The deal includes assumption of debt and future considerations (undisclosed). NeuroNexus, founded in 2004, specializes in high-value neural interface technology, components and systems for neuroscience and clinical markets. The entity possesses a vast portfolio of intellectual property, core technologies and capabilities to facilitate the development of innovative neural interface devices across a broad range of functions including neuromodulation, optical stimulation and targeted drug delivery applications. The acquisition is expected to boost Greatbatch’s foothold across cardiovascular and neuromodulation markets. The pooling of NeuroNexus’ technologies and Greatbatch’s capabilities will enable the combined entity to provide new world-class research products and systems to neuroscientists across the globe. Greatbatch expects the acquisition to be non-dilutive ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/23/gb-greatbatch-buying-neuronexus/92142/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/02/18/gild-gilead-sciences-analyt-maintains-neutral-on-shares/91806</link>
		<comments>http://www.stockbloghub.com/2012/02/18/gild-gilead-sciences-analyt-maintains-neutral-on-shares/91806#comments</comments>
		<pubDate>Sun, 19 Feb 2012 03:43:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[IPF]]></category>
		<category><![CDATA[Questar Corporation]]></category>
		<category><![CDATA[SPDR S&P International Financial Sector]]></category>
		<category><![CDATA[STR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91806</guid>
		<description><![CDATA[We have maintained a Neutral rating on Gilead Sciences, Inc. (GILD) following appraisal of fourth quarter and full year 2011 results. Gilead’s adjusted earnings per share of 92 cents (including stock option expense) for the fourth quarter of 2011 missed the Zacks Consensus Estimate by 8 cents, as higher revenues were offset by increased research and development (R&#38;D) expenses. However, earnings were 2 cents above the year-earlier figure of 90 cents. Fourth quarter revenues were up 10% from the prior-year quarter to $2.2 billion, spurred by higher product sales. Total revenue also edged past the Zacks Consensus Estimate of $2.19 billion. Other than the fourth quarter miss, 2011 was an eventful year for Gilead on all fronts, namely commercial, regulatory and financial. Gilead’s strategy of creating fixed-dose combinations of existing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/18/gild-gilead-sciences-analyt-maintains-neutral-on-shares/91806/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire and Sangamo BioSciences Cut a Deal</title>
		<link>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440</link>
		<comments>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440#comments</comments>
		<pubDate>Tue, 14 Feb 2012 15:22:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Sangamo Biosciences Inc]]></category>
		<category><![CDATA[SGMO]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91440</guid>
		<description><![CDATA[Shire plc (SHPGY) and Sangamo BioSciences, Inc. (SGMO) recently entered into a collaboration and license agreement for the development of products for hemophilia and other monogenic diseases. These products will be developed using Sangamo’s zinc finger DNA-binding protein (”ZFP”) technology. Terms of the Deal Shire will make an upfront payment of $13 million to Sangamo. Sangamo will also be eligible to receive milestone payments of up to $213.5 million based on the achievement of research, regulatory, development and commercial targets. Shire will pay Sangamo tiered double-digit royalties on product sales. As per the agreement, Shire will get exclusive global rights to ZFP therapeutics designed to target 4 genes for investigating curative therapies for hemophilia A and B. Shire also gets the right to designate 3 additional gene targets. While Sangamo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) Update on ViroPharma Industrial Facility</title>
		<link>http://www.stockbloghub.com/2012/02/13/vphm-update-on-viropharma-industrial-facility/91534</link>
		<comments>http://www.stockbloghub.com/2012/02/13/vphm-update-on-viropharma-industrial-facility/91534#comments</comments>
		<pubDate>Tue, 14 Feb 2012 04:55:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[PAS]]></category>
		<category><![CDATA[PepsiAmericas Inc.]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91534</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Cinryze’s industrial scale manufacturing facility. The regulatory body made three comments related to a portion of the cleaning validation for industrial scale manufacturing, of which only one requires additional unplanned activity. ViroPharma does not expect this activity to take much time to complete. The FDA also said that it has not finished reviewing the company’s January 2012 updated responses to observations specific to the September 2011 inspection of the Amsterdam facility. We note that ViroPharma undertook an expansion of the production capacity for Cinryze in 2009. In early 2010, the company submitted the Cinryze industrial scale manufacturing Prior Approval Supplement (PAS) to the FDA. In October 2010, the regulatory ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/13/vphm-update-on-viropharma-industrial-facility/91534/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Learns of Positive Results on Gedeon Drug</title>
		<link>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536</link>
		<comments>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536#comments</comments>
		<pubDate>Tue, 14 Feb 2012 04:54:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91536</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and partner Gedeon Richter recently presented positive top-line results on their antipsychotic candidate, cariprazine (RGH-188). Preliminary top-line results were presented from a phase III study that was conducted in patients with acute mania associated with bipolar I disorder. Results from the five-week multi-center, double-blind, placebo-controlled, parallel-group study showed that patients in the cariprazine arm experienced significant symptom improvement compared to patients in the placebo arm. The improvement was observed as early as the fifth day of treatment and at each subsequent time point studied. Cariprazine, a novel, orally active D2/D3 antagonist, was generally well tolerated. However, discontinuations due to adverse events were higher in the cariprazine arms compared to placebo. Forest Labs intends to analyze the data further. Results from this study were similar to those ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ZMH) Zimmer Holdings Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2012/02/06/zmh-zimmer-holdings-earnings-scorecard/91349</link>
		<comments>http://www.stockbloghub.com/2012/02/06/zmh-zimmer-holdings-earnings-scorecard/91349#comments</comments>
		<pubDate>Mon, 06 Feb 2012 20:32:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[PowerShares Dynamic Semiconductors]]></category>
		<category><![CDATA[PSI]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91349</guid>
		<description><![CDATA[The announcement of Zimmer Holdings’ (ZMH) fourth quarter and fiscal 2011 results as on January 26, 2012, has led analysts to revise their estimates lower for the first quarter of fiscal 2012. The scenario, however, improves for the second half and onwards. Previous Quarter Highlights Zimmer reported an adjusted EPS of $1.36 during the fourth quarter of fiscal 2011, up 7.1% year over year and a couple of cents ahead of the Zacks Consensus Estimate. During the reported quarter, the company recorded $108.0 million provision for claims related to the Durom Acetabular component, which has been taken into account in the adjusted figure. For the full year, the adjusted EPS increased 10.9% to $4.80, surpassing the Zacks Consensus Estimate of $4.78. Revenues were $1.17 billion, up 2.9% on a reported basis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/06/zmh-zimmer-holdings-earnings-scorecard/91349/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2012/02/06/jnj-johnson-johnson-earnings-scorecard/91297</link>
		<comments>http://www.stockbloghub.com/2012/02/06/jnj-johnson-johnson-earnings-scorecard/91297#comments</comments>
		<pubDate>Mon, 06 Feb 2012 17:32:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91297</guid>
		<description><![CDATA[Following the release of fourth quarter and full year 2011 results, most of the analysts covering Johnson &#38; Johnson (JNJ) have reduced their earnings estimates for 2012 and 2013. The revisions in estimates mainly reflect the guidance provided by the company. Fourth Quarter and Full Year 2011 Recap Johnson &#38; Johnson posted fourth quarter 2011 earnings (excluding special items) of $1.13 per share, three cents above the Zacks Consensus Estimate of $1.10 and 9.7% above the year-ago earnings of $1.03.. Johnson &#38; Johnson’s revenues for the fourth quarter increased 3.9% year-over-year to $16.3 billion. Revenues were in-line with the Zacks Consensus Estimate. Full year 2011 earnings came in at $5.00, 5% above the year-ago earnings of $4.76 per share and 4 cents above the Zacks Consensus Estimate. Earnings came in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/06/jnj-johnson-johnson-earnings-scorecard/91297/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) St. Jude Medical Fourth Quarter 2011 Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2012/02/06/stj-st-jude-medical-fourth-quarter-2011-earnings-scorecard/91302</link>
		<comments>http://www.stockbloghub.com/2012/02/06/stj-st-jude-medical-fourth-quarter-2011-earnings-scorecard/91302#comments</comments>
		<pubDate>Mon, 06 Feb 2012 17:32:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91302</guid>
		<description><![CDATA[Medical devices major St. Jude Medical’s (STJ) fourth-quarter 2011 adjusted earnings per share of 86 cents beat the Zacks Consensus Estimate by a couple of cents and exceeded the year-ago earnings of 75 cents. Highlights from the Quarter Profit (as reported) for the fourth quarter slipped roughly 21% year over year to $163.4 million (or 51 cents a share) as higher sales were overshadowed by lofty special charges. Revenues rose 4% year over year to $1,406.9 million, beating the Zacks Consensus Estimate of $1,400 million. Double-digit growth across the company’s Atrial Fibrillation, Cardiovascular and Neuromodulation segments was partly masked by the decline in the core Cardiac Rhythm Management (“CRM”) division. Revenues from the CRM division fell 4% year over year, indicating sustained softness in the U.S. ICD market. ICD revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/06/stj-st-jude-medical-fourth-quarter-2011-earnings-scorecard/91302/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Intuitive Surgical 2011 Fourth Quarter Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2012/02/02/isrg-intuitive-surgical-2011-fourth-quarter-earnings-scorecard/91177</link>
		<comments>http://www.stockbloghub.com/2012/02/02/isrg-intuitive-surgical-2011-fourth-quarter-earnings-scorecard/91177#comments</comments>
		<pubDate>Thu, 02 Feb 2012 19:41:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91177</guid>
		<description><![CDATA[Intuitive Surgical (ISRG) reported favorable fourth-quarter 2011 results. Earnings per share came in at $3.75, beating the Zacks Consensus Estimate of $3.34 and the year-ago earnings of $3.02. Net income climbed 24.8% year over year to $151.2 million. Fourth Quarter Review Revenues increased 28% year over year to $496.8 million, beating the Zacks Consensus Estimate of $483 million. Instruments and accessories revenues were $196 million in the quarter, up 30% year over year. Worldwide procedures increased 27%. The company posted total systems revenue of $225 million in the quarter, up 27%. Services/Training revenues were $75 million in the quarter, up 24% year over year, primarily due to growth in the installed base of da Vinci Surgical systems. Agreement – Estimate Revisions Estimates for fiscal 2012 demonstrate an upward trend among ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/02/isrg-intuitive-surgical-2011-fourth-quarter-earnings-scorecard/91177/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Now is the Time to Buy Healthcare Stocks</title>
		<link>http://www.stockbloghub.com/2012/02/02/isrg-now-is-the-time-to-buy-healthcare-stocks/91149</link>
		<comments>http://www.stockbloghub.com/2012/02/02/isrg-now-is-the-time-to-buy-healthcare-stocks/91149#comments</comments>
		<pubDate>Thu, 02 Feb 2012 19:38:38 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91149</guid>
		<description><![CDATA[I’ve been talking a lot lately about the $4 trillion that’s about to fall into the laps of businesses in the healthcare sector due to the number of Baby Boomers who are now turning 65. And we know that the older we get, the more we spend on healthcare. Consider: The average senior takes between two and seven prescription medications. Two out of three seniors will suffer a physical or mental impairment. One out of three seniors will spend time in a nursing home. All of those things cost money – not to mention, chemotherapy, insulin, rehab stays, regular doctor appointments, weight loss programs and nutritional supplements. That’s why it’s a great time to put money to work in the sector. Revenue and earnings are going to explode higher in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/02/isrg-now-is-the-time-to-buy-healthcare-stocks/91149/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WLP) These Healthcare Insurance Stocks Are Ready to Rise</title>
		<link>http://www.stockbloghub.com/2012/01/31/wlp-these-healthcare-insurance-stocks-are-ready-to-rise/28975</link>
		<comments>http://www.stockbloghub.com/2012/01/31/wlp-these-healthcare-insurance-stocks-are-ready-to-rise/28975#comments</comments>
		<pubDate>Tue, 31 Jan 2012 16:47:13 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AEE]]></category>
		<category><![CDATA[Ameren Corporation]]></category>
		<category><![CDATA[CI]]></category>
		<category><![CDATA[CIGNA Corporation]]></category>
		<category><![CDATA[Coventry Health Care Inc.]]></category>
		<category><![CDATA[CVH]]></category>
		<category><![CDATA[HealthSpring Inc]]></category>
		<category><![CDATA[HS]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[PCG]]></category>
		<category><![CDATA[PEG]]></category>
		<category><![CDATA[PG & E Corporation]]></category>
		<category><![CDATA[Public Service Enterprise Group Inc]]></category>
		<category><![CDATA[UAM]]></category>
		<category><![CDATA[Universal American Corp]]></category>
		<category><![CDATA[WellPoint Inc.]]></category>
		<category><![CDATA[WLP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28975</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, February 24, 2010: Issue #1203 Healthcare Reform 2.0 is here – this time without as much pork. Good thing, too. Pork is loaded with cholesterol, which increases heart disease, healthcare costs and… well, you get the idea. The President released his revised plan for healthcare reform earlier this week. And while the new proposal is similar to the Senate’s on Christmas Eve, it eliminates some of the pork to Nebraska and other special interests. I’m not going to politicize, though. I’ll leave that to the wackos on talk radio and cable “news” programs. I’ll just focus on what the plan means to health insurers – and investors. Stemming the Tide of Health Insurance Premium Hikes Obama has stated that his proposal is an opening ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/31/wlp-these-healthcare-insurance-stocks-are-ready-to-rise/28975/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/01/30/myl-mylan-incorporated-bull-of-the-day/91048</link>
		<comments>http://www.stockbloghub.com/2012/01/30/myl-mylan-incorporated-bull-of-the-day/91048#comments</comments>
		<pubDate>Mon, 30 Jan 2012 17:11:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91048</guid>
		<description><![CDATA[Mylan, Inc. (MYL) is one of the leading players in the US generics market. The company holds immense potential as many blockbuster drugs have begun to go off-patent and many more will lose patent exclusivity in the next few years. Moreover, we are encouraged by Mylan&#8217;s geographic reach and product depth along with a robust generic product pipeline. We believe the generic segment will post strong sales in 2012 benefiting from a slew of product launches already lined up. We have therefore upgraded our rating on Mylan from Neutral to Outperform to reflect our overall bullish stance for generic makers. Our target price for the stock is $26.00. MYLAN INC (MYL): Free Stock Analysis Report]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/30/myl-mylan-incorporated-bull-of-the-day/91048/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ZOLL) ZOLL Medical Corporation &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/01/27/zoll-zoll-medical-corporation-bull-of-the-day-4/90966</link>
		<comments>http://www.stockbloghub.com/2012/01/27/zoll-zoll-medical-corporation-bull-of-the-day-4/90966#comments</comments>
		<pubDate>Fri, 27 Jan 2012 17:26:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90966</guid>
		<description><![CDATA[We retain our Outperform recommendation on ZOLL Medical Corp. (ZOLL) following its forecast-topping first quarter results. Revenues and earnings for the quarter beat the Zacks Consensus Estimates, driven by strong sales from the company&#8217;s LifeVest and temperature management businesses. The company witnessed healthy sales across the North American hospital and pre-hospital markets. We are pleased with ZOLL&#8217;s solid fundamentals and its broad product range. Moreover, its significant international presence should also drive growth. The company has completed multiple acquisitions and is seeking more such lucrative transactions to aid growth. Management&#8217;s outlook for fiscal 2012 is encouraging with sales are expected to grow at a healthy double-digit clip on the strength of the company&#8217;s core defibrillator business. ZOLL MEDICAL CO (ZOLL): Free Stock Analysis Report]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/27/zoll-zoll-medical-corporation-bull-of-the-day-4/90966/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(UNH) UnitedHealth Group &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/01/25/unh-unitedhealth-group-bull-of-the-day-3/90754</link>
		<comments>http://www.stockbloghub.com/2012/01/25/unh-unitedhealth-group-bull-of-the-day-3/90754#comments</comments>
		<pubDate>Wed, 25 Jan 2012 18:02:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90754</guid>
		<description><![CDATA[UnitedHealth Group&#8217;s (UNH) fourth-quarter 2011 earnings came in substantially ahead of the Zacks Consensus Estimate, led by strong revenue growth from the UnitedHealthcare and Optum businesses, partially offset by higher medical costs. The company ended the year 2011 with better performances in virtually every meaningful metric: membership, revenues, MLR, operating margins and cash flow. The company strengthened its key capabilities to respond to the emerging growth opportunities. These initiatives has been taken to expand its Medicaid and Medicare business and for growing the health service business. Though certain headwinds such as high unemployment, growing medical cost, pressure from Health Care overhaul, etc. remains, we believe the company will beat the odds given its diversified business model with leading market share positions in the Commercial, Medicare and Medicaid markets. A solid ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/25/unh-unitedhealth-group-bull-of-the-day-3/90754/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DVA) DaVita Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/01/25/dva-davita-incorporated-bull-of-the-day/90800</link>
		<comments>http://www.stockbloghub.com/2012/01/25/dva-davita-incorporated-bull-of-the-day/90800#comments</comments>
		<pubDate>Wed, 25 Jan 2012 18:01:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Specialized Health Services]]></category>
		<category><![CDATA[DaVita Inc.]]></category>
		<category><![CDATA[DVA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90800</guid>
		<description><![CDATA[We are upgrading our recommendation on DaVita, Inc. (DVA) to Outperform based on the company&#8217;s strong cash flows and strategic acquisitions. The new bundled ESRD payment system is also expected to be a long-term positive. The company&#8217;s third-quarter earnings slightly exceeded the Zacks Consensus Estimate on the back of strong top-line growth, partially offset by higher operating expenses. Moreover, a strong cash position expands the potential for meaningful M&#38;A. While the acquisition of DSI should bring in new opportunities in most states, the company has to divest some of its centers as a condition. Nevertheless, we believe downside from current levels is likely limited. Our six-month target price of $96.00 equates to 19.0x our earnings estimate for 2011. This price target implies an expected total return of 20.3% over that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/25/dva-davita-incorporated-bull-of-the-day/90800/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Intuitive Squarely Beats Earnings Expectations</title>
		<link>http://www.stockbloghub.com/2012/01/25/isrg-intuitive-squarely-beats-earnings-expectations/90562</link>
		<comments>http://www.stockbloghub.com/2012/01/25/isrg-intuitive-squarely-beats-earnings-expectations/90562#comments</comments>
		<pubDate>Wed, 25 Jan 2012 17:58:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90562</guid>
		<description><![CDATA[Intuitive Surgical (ISRG) reported fourth quarter and fiscal 2011 earnings per share of $3.75 and $12.32, respectively, beating the Zacks Consensus Estimates of $3.34 and $11.89, respectively, while surpassing the corresponding year-ago results of $3.02 and $9.47. Revenues Intuitive reported revenues of $496.8 million and $1,757.3 million for the fourth quarter and fiscal 2011, respectively, up 28% and 24% year over year. The results beat the Zacks Consensus Estimates of $483 million and $1,741 million, respectively. On a segment basis, the company reported revenues from instruments and accessories of $196 million, up 30% year over year, in the fourth quarter. The growth was driven by a 27% year-over-year increase in da Vinci surgical procedures. Revenues from sales of systems were $225 million, up 27% year over year. The increase in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/25/isrg-intuitive-squarely-beats-earnings-expectations/90562/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Earnings Season in Full Swing &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2012/01/24/abt-earnings-season-in-full-swing-earnings-preview/90668</link>
		<comments>http://www.stockbloghub.com/2012/01/24/abt-earnings-season-in-full-swing-earnings-preview/90668#comments</comments>
		<pubDate>Tue, 24 Jan 2012 17:21:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Automatic Data Processing Inc]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Colgate-Palmolive Company]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[DeVry Inc.]]></category>
		<category><![CDATA[DV]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90668</guid>
		<description><![CDATA[Earnings Preview 1/20/12 Earnings season will be in full swing this week. 422 firms are scheduled to report, and 117 of those will be members of the S&#38;P 500. By the end of the week we should have a very good handle on just how weak or strong this earnings season will be. The firms reporting next week read like a who’s who of American industry.  They.include: Abbott Labs (ABT), Apple (AAPL), Automatic Data Processing (ADP), AT&#38;T (T), Boeing  (BA), Bristol Myers (BMY), Caterpillar (CAT), CSX (CSX), Chevron (CVX), Colgate Palmolive (CL), Conoco Phillips (COP &#8211; Analyst Report) and DuPont (DD) – and that is just in the first four letters of the alphabet! It will also be a moderate week for economic data.  Things will be slow early in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/24/abt-earnings-season-in-full-swing-earnings-preview/90668/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Mixed Earnings, Greece May Slip Markets</title>
		<link>http://www.stockbloghub.com/2012/01/24/jnj-mixed-earnings-greece-may-slip-markets/90717</link>
		<comments>http://www.stockbloghub.com/2012/01/24/jnj-mixed-earnings-greece-may-slip-markets/90717#comments</comments>
		<pubDate>Tue, 24 Jan 2012 17:20:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Coach Inc.]]></category>
		<category><![CDATA[COH]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90717</guid>
		<description><![CDATA[With nothing major on the domestic economic calendar, headlines about Greece’s as-yet unsuccessful negotiations with its bondholders to restructure its private debt may get some traction. But today’s market action will be mostly about the slew of mixed earnings reports from a &#8220;who’s who&#8221; of corporate America. We also have President Obama’s State of the Union address later this evening. We have 5 Dow components reporting results this morning, of which three came out with positive surprises, while two came up short. Johnson &#38; Johnson (JNJ) came out with a positive EPS surprise on in-line revenue numbers. McDonald’s (MCD) beat earnings expectations on roughly in-line revenue numbers. DuPont (DD) came out with a modest earnings surprise, though the chemicals giant’s top-line came short of expectations. The company had lowered expectations ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/24/jnj-mixed-earnings-greece-may-slip-markets/90717/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Jan 24: Day of Earnings! &#8211; Economic Highlights</title>
		<link>http://www.stockbloghub.com/2012/01/24/jnj-jan-24-day-of-earnings-economic-highlights/90730</link>
		<comments>http://www.stockbloghub.com/2012/01/24/jnj-jan-24-day-of-earnings-economic-highlights/90730#comments</comments>
		<pubDate>Tue, 24 Jan 2012 17:19:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Coach Inc.]]></category>
		<category><![CDATA[COH]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90730</guid>
		<description><![CDATA[With nothing major on the domestic economic calendar, headlines about Greece’s as-yet unsuccessful negotiations with its bondholders to restructure its private debt may get some traction. But today’s market action will be mostly about the slew of mixed earnings reports from a &#8220;who’s who&#8221; of corporate America. We also have President Obama’s State of the Union address later this evening. We have 5 Dow components reporting results this morning, of which three came out with positive surprises, while two came up short. Johnson &#38; Johnson (JNJ) came out with a positive EPS surprise on in-line revenue numbers. McDonald’s (MCD) beat earnings expectations on roughly in-line revenue numbers. DuPont (DD) came out with a modest earnings surprise, though the chemicals giant’s top-line came short of expectations. The company had lowered expectations ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/24/jnj-jan-24-day-of-earnings-economic-highlights/90730/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(UNH) UnitedHealth Group &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/01/23/unh-unitedhealth-group-bull-of-the-day-2/90632</link>
		<comments>http://www.stockbloghub.com/2012/01/23/unh-unitedhealth-group-bull-of-the-day-2/90632#comments</comments>
		<pubDate>Mon, 23 Jan 2012 17:30:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90632</guid>
		<description><![CDATA[UnitedHealth Group&#8217;s (UNH) fourth-quarter 2011 earnings came in substantially ahead of the Zacks Consensus Estimate, led by strong revenue growth from the UnitedHealthcare and Optum businesses, partially offset by higher medical costs. The company ended the year 2011 with better performances in virtually every meaningful metric: membership, revenues, MLR, operating margins and cash flow. The company strengthened its key capabilities to respond to the emerging growth opportunities. These initiatives has been taken to expand its Medicaid and Medicare business and for growing the health service business. Though certain headwinds such as high unemployment, growing medical cost, pressure from Health Care overhaul, etc. remains, we believe the company will beat the odds given its diversified business model with leading market share positions in the Commercial, Medicare and Medicaid markets. A solid ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/23/unh-unitedhealth-group-bull-of-the-day-2/90632/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HS) HealthSpring Shareholders Approve CIGNA Merger</title>
		<link>http://www.stockbloghub.com/2012/01/22/hs-healthspring-shareholders-approve-cigna-merger/90396</link>
		<comments>http://www.stockbloghub.com/2012/01/22/hs-healthspring-shareholders-approve-cigna-merger/90396#comments</comments>
		<pubDate>Sun, 22 Jan 2012 17:55:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AET]]></category>
		<category><![CDATA[Aetna Inc.]]></category>
		<category><![CDATA[CI]]></category>
		<category><![CDATA[CIGNA Corporation]]></category>
		<category><![CDATA[HealthSpring Inc]]></category>
		<category><![CDATA[HS]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[WellPoint Inc.]]></category>
		<category><![CDATA[WLP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90396</guid>
		<description><![CDATA[The acquisition of HealthSpring Inc. (HS) by CIGNA Corp. (CI) has received the approval of the former company&#8217;s shareholders. The approval came from approximately 83% of the shareholders, at a special meeting held on January 12, 2012. The acquisition was announced by Cigna in October last year. HealthSpring’s vast Medicare business with a trusted brand name made it the best fit for Cigna, which intends to foray into the rapidly growing Medicare Advantage business. With this acquisition, valued at approximately $3.8 billion, Cigna will get access to 800,000 Medicare prescription customers and 340,000 Medicare advantage customers. Cigna, the fourth largest health insurer in U.S., had been historically biased towards commercial business (primarily self funded) and averse to government businesses (Medicare and Medicaid). But it is now targeting the government businesses. This shift ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/22/hs-healthspring-shareholders-approve-cigna-merger/90396/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIIB) Biogen Analyst Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609</link>
		<comments>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609#comments</comments>
		<pubDate>Sat, 21 Jan 2012 20:38:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PIMCO Municipal Income Fund II]]></category>
		<category><![CDATA[PML]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90609</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen’s largest product, Avonex, posted sales of $2,518.4 million, up 8.4%, in 2010. We expect Avonex to continue contributing significantly to the top-line thanks to price increases, focused marketing effort, expansion into new markets and positive clinical data. Meanwhile, Tysabri, the company’s second MS product, continues to see an increase in patients despite carrying a “black box” warning for the risk of progressive multifocal leukoencephalopathy (PML) and other cautionary language. Tysabri posted $1.2 billion in sales in 2010. Tysabri’s launch in new markets like India, Brazil, Argentina, the Middle East and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/21/biib-biogen-analyst-neutral-on-shares/90609/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ILMN) Two Major Biotech Trends In 2012</title>
		<link>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438</link>
		<comments>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438#comments</comments>
		<pubDate>Thu, 19 Jan 2012 23:34:54 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90438</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, January 18, 2012: Issue #1689 The workers at the restaurants and bars around Union Square in San Francisco have likely just about caught their breath. The 10,000 or so businesspeople who descended on the neighborhood for the J.P. Morgan Healthcare Conference drank their fill of Patron, ate a few tons of filets and guzzled thousands of gallons of Starbucks coffee. What makes the conference such a big deal is that it’s the largest and most important investor event of the year in the healthcare sector. There are other healthcare conferences put on by investment banks, but nothing comes close to the quality and number of companies and attendees at JPM. There were two important takeaways that emerged from the conference – themes ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Corporation &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/01/18/celg-celgene-corporation-bull-of-the-day-2/90404</link>
		<comments>http://www.stockbloghub.com/2012/01/18/celg-celgene-corporation-bull-of-the-day-2/90404#comments</comments>
		<pubDate>Wed, 18 Jan 2012 20:45:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90404</guid>
		<description><![CDATA[We are maintaining our Outperform recommendation on Celgene Corp. (CELG) following impressive preliminary results disclosed for the fourth quarter (adjusted EPS up 46%) and full year 2011 (adjusted EPS up 36%). Preliminary adjusted revenues in the final quarter of 2011 came in at $1.28 billion, 22% above the year-ago figure. For 2011, sales came in at $4.8 billion, up 34%. The company also gave a bright outlook for 2012 with adjusted earnings expected to improve by 25%. We believe that Celgene, driven by its oncology portfolio and robust pipeline, should easily achieve the 2012 guidance. We believe that the current price represents an attractive entry point for long-term investors. Based on 2012 P/E estimates, the stock is trading at 17.4x earnings, compared to the industry average of 28.1. Our target ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/18/celg-celgene-corporation-bull-of-the-day-2/90404/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARQL) Company News for January 18, 2012 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416</link>
		<comments>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416#comments</comments>
		<pubDate>Wed, 18 Jan 2012 20:42:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ARQL]]></category>
		<category><![CDATA[ArQule Inc]]></category>
		<category><![CDATA[Blackbaud Inc]]></category>
		<category><![CDATA[BLKB]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Venoco Inc]]></category>
		<category><![CDATA[VQ]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90416</guid>
		<description><![CDATA[•    Bio technology company ArQule Inc.’s (NASDAQ:ARQL) share prices gained 11.91% to close at $6.67 after the company&#8217;s experimental treatment for liver cancer reported a positive outcome in its Phase II trial •    Share prices of discount carrier Sprint Airlines Inc. (NASDAQ:SAVE) declined 5.53% after the company announced plans to sell 11 million shares in a secondary offering •    Global provider of software Blackbaud Inc. (NASDAQ:BLKB) will buy fund raising software maker Convio Inc. (NASDAQ:CNVO) for $16 per share. Following the news, shares of Convio rocketed up 48% to close at $15.89 a share •    ISTA Pharmaceuticals Inc.’s shares (NASDAQ:ISTA) gained 13.07% after Valeant Pharmaceuticals International Inc. (NYSE:VRX) increased its hostile-takeover bid for ISTA to $7.50 a share •    Shares of natural gas firm Venoco Inc. (NYSE:VQ) surged 29.91% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VPHM) ViroPharma  Drug Earns Priority Review</title>
		<link>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265</link>
		<comments>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265#comments</comments>
		<pubDate>Mon, 16 Jan 2012 23:37:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90265</guid>
		<description><![CDATA[ViroPharma Inc. (VPHM) recently announced that the Canadian regulatory body has granted priority review status to the company’s new drug submission (NDS) for Cinryze. ViroPharma is seeking the drug’s approval for the treatment of prevention, pre-procedure prevention, and treatment of attacks of hereditary angioedema (HAE) in patients who are six years or older. The company expects Health Canada to complete its review of Cinryze in the second half of 2012. We note that Cinryze is currently marketed in the US for the prevention of angioedema attacks in adolescent and adult patients with HAE. In the European Union (EU), the same drug is marketed for the treatment of prevention, pre-procedure prevention, and treatment of attacks of HAE in adolescents and adult patients. We view this development as a positive for ViroPharma, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/16/vphm-viropharma-drug-earns-priority-review/90265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Expands with New Deals</title>
		<link>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111</link>
		<comments>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111#comments</comments>
		<pubDate>Fri, 13 Jan 2012 21:09:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90111</guid>
		<description><![CDATA[In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement, the company seeks to obtain worldwide exclusive rights for biomarkers for gene mutation. In collaboration with the Tennessee-based molecular diagnostics company Insight Genetics, Qiagen will provide a genetic test with a biomarker for non-small cell lung cancers (NSCLC) that express the abnormal anaplastic lymphoma kinase (ALK) gene. Meanwhile, under the agreement with Maryland-based Personal Genome Diagnostics, Qiagen’s 89% subsidiary Ipsogen obtained rights to genetic testing for mutations of the IDH1 and IDH2 genes for brain cancers, acute myelogenous leukemia (AML) and other malignancies. With the companion diagnostics market expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ITMN) InterMune Fourth Quarter Esbriet Sales Snapshot</title>
		<link>http://www.stockbloghub.com/2012/01/13/itmn-intermune-fourth-quarter-esbriet-sales-snapshot/89940</link>
		<comments>http://www.stockbloghub.com/2012/01/13/itmn-intermune-fourth-quarter-esbriet-sales-snapshot/89940#comments</comments>
		<pubDate>Fri, 13 Jan 2012 20:59:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[InterMune Inc]]></category>
		<category><![CDATA[IPF]]></category>
		<category><![CDATA[ITMN]]></category>
		<category><![CDATA[NPP]]></category>
		<category><![CDATA[Nuveen Performance Plus Municipal Fund Inc]]></category>
		<category><![CDATA[SPDR S&P International Financial Sector]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89940</guid>
		<description><![CDATA[InterMune, Inc. (ITMN) recently reported preliminary fourth quarter revenue for its potential blockbuster drug Esbriet. Esbriet is approved in the European Union (EU) for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF). The drug has been launched first in Germany in September 2011. InterMune also announced updated data from the drug’s RECAP study. Preliminary Esbriet Update InterMune reported Esbriet revenue of $2.8 million since launch in September 2011, of which $2.7 million was generated in Germany. Management announced that 1,022 new patients started Esbriet therapy across EU at the end of 2011. Of these, 612 patients have been given Esbriet in Germany and 410 patients have enrolled in the named patient program (NPP) outside Germany. Under the NPP program qualified physicians can make Esbriet available to IPF patients in EU ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/itmn-intermune-fourth-quarter-esbriet-sales-snapshot/89940/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

